Source-grounded facts extracted from Alaunos Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Alaunos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 9, 2026, Alaunos Therapeutics, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires listed companies to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice states that the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, reported stockholders’ equity of $2,153,000. As of the date of the Notice”
Material Agreements
Alaunos Therapeutics, Inc. terminated Engagement Letter dated August 14, 2023 with Cantor Fitzgerald & Co. valued at Termination of engagement letter for strategic transactions advisory; no fees payable upon terminati (effective 2026-01-08).
“On January 8, 2026, the Company delivered written notice to Cantor Fitzgerald & Co. (“Cantor”) terminating, effective immediately, the engagement letter dated August 14, 2023 (the “Engagement Letter”), pursuant to which Cantor had been engaged as the Company’s exclusive financial advisor in connection with the exploration of potential strategic transactions.”
Robert Hofmeister resigned as director at Alaunos Therapeutics, Inc..
“Robert Hofmeister, Ph.D. Resignation On April 15, 2025, Dr. Hofmeister resigned as a member of the board of directors (the “Board”) of Alaunos Therapeutics, Inc. (the “Company”) with immediate effect.”
Ferdinand Groenewald was appointed as Vice President, Finance at Alaunos Therapeutics, Inc..
“On February 22, 2024, the Company and Ferdinand Groenewald entered into a consulting agreement (the “Consulting Agreement”), effective February 22, 2024, pursuant to which Mr. Groenewald will lead accounting and financial reporting activities of the Company. Mr. Groenewald will serve as the Company’s Vice President, Finance.”
Michael Wong resigned as Vice President, Finance at Alaunos Therapeutics, Inc..
“On February 15, 2024, Michael Wong gave notice of his resignation as Vice President, Finance, of Alaunos Therapeutics, Inc. (the "Company"), effective February 23, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.